Effects of Topical Loteprednol Etabonate on Tear Cytokines and Clinical Outcomes in Moderate and Severe Meibomian Gland Dysfunction: Randomized Clinical Trial

Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status

“…Previous studies showed that an improvement of MGD was observed after the use of topical medications such as antibiotics and steroids, which have been routinely used during the postoperative period . Recently, we demonstrated that topical steroids provided anti‐inflammatory effects and clinical benefits in the patients with moderate and severe MGD, showing control of inflammatory cytokines . Therefore, the patients in group I generally appeared to have control of ocular surface inflammation with postoperative medication at tear sampling time.…”

Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

“…35,36 Previous studies have confirmed the relatively lower risk of IOP elevation with LE compared with other ocular steroids, including studies in known steroid responders. [37][38][39][40][41][42][43][44][45] Limitations of this analysis included the lack of either a non-active control, or a control of a different drug category and the 2-week follow-up period. The study treatments both contained the same antibacterial (tobramycin), and a highly effective corticosteroid (loteprednol etabonate or dexamethasone).…”

Dysfunctional tear syndrome

“…Clinicians are advised to consider formulations that may decrease the risk of steroid-associated adverse effects [e.g., fluorometholone, loteprednol etabonate, and low-dosage dexamethasone (0.01%)] in the treatment of DED and blepharitis/MGD [105,126–128,213]. …”